The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.
about
Resistant mechanisms to BRAF inhibitors in melanomaTargeting inflammation in pancreatic cancer: Clinical translationMerkel Cell Carcinoma: Epidemiology, Target, and TherapyNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityAspirin and other NSAIDs as chemoprevention agents in melanomaUnderstanding the biology of melanoma and therapeutic implicationsBig opportunities for small molecules in immuno-oncology.Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions.Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaTargeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanomaA Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread-Identification of a Promising Novel therapeutic target.Multiplying therapies and reducing toxicity in metastatic melanoma.Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cellsImmunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patientsLong-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells.Nivolumab: a review of its use in patients with malignant melanoma.Potential Use of γδ T Cell-Based Vaccines in Cancer Immunotherapy.Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway.Pembrolizumab: A Review in Advanced Melanoma.ERBB3 is required for metastasis formation of melanoma cells.Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential.Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma.CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.Breakthrough therapies in melanoma.Anorectal mucosal melanoma.BRAF in early stage melanoma: rationale for testing and treatment?
P2860
Q26739717-04500209-0CF9-4B91-B9B0-63C32829803DQ26751686-9EFC0FAA-8164-4FE9-B18B-A48FA79FFDE1Q26824521-99521292-7C0E-442B-8207-B5EAADFE6695Q26992272-69A89417-32DB-46F1-8A82-FD15CD746800Q33725012-422EB973-29DA-4B25-91C8-FCDCEABFEC39Q33978378-7A33C6C2-93F7-47DE-BB20-8F0CAB69A16CQ34487689-FF647B61-B07A-4D83-9C1A-3BEF14B6B3D1Q34654508-A6E2D07D-BDD8-4995-AD96-EEC417E81BAAQ34786402-0E852F1F-878A-458A-B181-6E692A75E09CQ35434352-247DD7F8-6136-43AB-BC45-E0DCE161CCDFQ35692123-65A43FF0-938B-4133-B0B6-EA066E2D31DEQ36037996-BC0FFEA2-6CB5-40ED-8B8C-CB295B92FF36Q36216263-6DF0A2B5-A6B5-4E75-B913-4E3EACBF2465Q36414039-FE429DE4-42EC-4729-919C-4D4082161505Q37174695-B9665B06-0CE7-4F43-AA13-F5F6A75C00C6Q38171355-660396D7-B5F5-421B-A25A-54DC4D16C9DDQ38229303-51717EEF-9064-4316-BCF9-8A8D9DB3B1E2Q38265506-D21ED330-FBFB-44D0-8E17-94D28734DF14Q38284898-839BA2A5-C483-403F-86AF-F3A071B6B4BCQ38723299-F2FAE9F0-26F0-4A3A-A7E5-C8F77A0B0519Q38977527-66D9CAF4-A84A-4B2F-ABCB-8E17AEB236FAQ39051823-2D54104A-C963-4B74-A1AC-31FF82D0F8A6Q40282288-D3483B75-969A-49C7-9A77-4526DBF3014EQ41992352-E4FB8FE5-8BC2-42A6-8297-63E557F46639Q42378351-7664EA72-A3E0-4EB5-AA91-F423B397F793Q47443248-9C6BDC98-33E4-4D5E-BC6C-DA68EC191C5BQ48937070-AFE115E5-180D-406A-BD13-B8F71B29403CQ52680468-8C6335F8-81DD-42A8-B806-C7C64540E497Q54259192-6101CD52-9F2E-4868-9760-FDE6D236F81D
P2860
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The intersection of immune-dir ...... e have been, are, and will be.
@en
type
label
The intersection of immune-dir ...... e have been, are, and will be.
@en
prefLabel
The intersection of immune-dir ...... e have been, are, and will be.
@en
P2860
P1476
The intersection of immune-dir ...... e have been, are, and will be.
@en
P2093
Patricia M Lorusso
Ryan J Sullivan
P2860
P304
P356
10.1158/1078-0432.CCR-13-2151
P407
P577
2013-10-01T00:00:00Z